Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs PSNL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 5 – 1 PSNL Matrix Metrics: VCYT 7 – 3 PSNL

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Personalis, Inc. (PSNL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas PSNL carries 39.6/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin).

  • Growth vs. Quality Trade-Off: VCYT earns the overall head-to-head edge with a stronger Unified Composite Score (49.1/100 HOLD vs. PSNL 39.6/100 SELL) and 3.01β · 199% Vol risk profile, whereas PSNL leads top-line expansion (+76.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs PSNL
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
PSNL NASDAQ
Personalis, Inc. Common Stock
Services-Medical Laboratories
$14.80
-5.79% 1D
Market Cap $1.7B
TTM Revenue $81M
Forward P/E N/M
Beta / 30D Vol 1.86β · 21% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 30.0 Fund 48.0 Flow 58.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.5%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $15.80 · SMA50: $16.03

6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 PSNL)

Columns: Metric · VCYT · PSNL
1. Valuation Multiples VCYT
Forward P/E 15.3x N/M
Trailing P/E 15.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.1x 20.3x
2. Growth & Scale VCYT
Revenue Growth (YoY) +15.1% +76.6%
Earnings Growth (YoY) +58.3% +0.0%
TTM Revenue (USD) $582M $81M
Market Cap $2.0B $1.7B
3. Profitability & Quality VCYT
Gross Margin 74.2% 16.7%
Operating Margin 15.0% -156.7%
Net Profit Margin 21.8% -147.7%
Return on Equity (ROE) 9.4% -62.1%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$108M
Cash Flow Margin 27.8% N/A
Net Cash / Leverage $159M Net Cash $61M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PSNL
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 197.3% (47th %ile) 35.2% (2nd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.02x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 59.2% of Rev ($344M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (7) vs PSNL (3)
Institutional Metric VCYT PSNL Criterion Row Edge
Market Capitalization
Scale
$2.0B $1.7B Larger Scale VCYT
Trailing P/E Ratio
Valuation
15.8x N/M Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +76.6% Higher Growth PSNL
Operating Margin (TTM)
Profitability
15.0% -156.7% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -147.7% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -62.1% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 71% ($5–$19) Stronger Trend PSNL
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 1.86β · 21% Vol Lower Realized Risk PSNL
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 39.6 / 100 (SELL) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $81M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 16.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 20.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$108M ($61M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSNL +38.89 pp
VCYT: -44.32% · PSNL: -5.43%
3M Horizon PSNL +47.38 pp
VCYT: -40.98% · PSNL: +6.4%
6M Horizon PSNL +162.38 pp
VCYT: -42.14% · PSNL: +120.24%
1Y Horizon PSNL +134.52 pp
VCYT: -39.78% · PSNL: +94.74%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue PSNL Revenue VCYT Op. Margin PSNL Op. Margin Margin Leader
FY2018 $90M $40M -24.2% -36.5% VCYT
FY2019 $120M $70M -12.6% -34.4% VCYT
FY2020 $120M $80M -30.1% -53.6% VCYT
FY2021 $220M $90M -37.3% -76.4% VCYT
FY2022 $300M $70M -13.9% -177.6% VCYT
FY2023 $360M $70M -23.8% -149.6% VCYT
FY2024 $450M $80M 3.6% -80.7% VCYT
FY2025 $520M $70M 11.2% -126.4% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PSNL CONSOLIDATION
87d in phase · OBV NEUTRAL
Current IV 35.2%
IV Percentile 2nd %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PSNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
PSNL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.7B market capitalization and -156.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs PSNL Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Personalis, Inc. (PSNL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas PSNL carries 39.6/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin). Growth vs. Quality Trade-Off: VCYT earns the overall head-to-head edge with a stronger Unified Composite Score (49.1/100 HOLD vs. PSNL 39.6/100 SELL) and 3.01β · 199% Vol risk profile, whereas PSNL leads top-line expansion (+76.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with PSNL at +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while PSNL shifted +75.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSNL.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus PSNL (-62.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, PSNL carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.86β · 21% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.